File image of medical staff at isolation ward where 3 patients were admitted for suspected coronavirus infection, in New Delhi | ANI
File image of medical staff at an isolation ward where three patients were admitted for suspected coronavirus infection in New Delhi | ANI
Text Size:

New Delhi: Pharmaceutical companies have given the Narendra Modi government a list of 57 medicines that are likely to go out of stock following the shutdown in China due to the coronavirus outbreak.

The medicines include commonly used antibiotics and menopausal medication to vitamin pills.

The companies Monday handed over the list to a committee formed by the government on 6 February to tackle “drug security concerns”.

The committee had convened a meeting with the drugmakers Monday where the latter said the stocks of active pharmaceutical ingredients (APIs), or bulk drugs, will get over within the next three months, ThePrint has learnt.

Chemists’ organisations, however, believe the shortage of drugs won’t reach the consumer before the next six months.

The list of APIs, accessed by ThePrint, contains antibiotics such as Azithromycin, Amoxicillin, Ofloxacin, Gentamicin and Metronidazole, neuropathic drug Gabapentin, vitamin tablets and capsules such as B12, B1, B6, and E, female hormone progesterone and anti-cardiac arrest drug Atorvastatin, among others.

Indian drugmakers import around 70 per cent of their total bulk drugs from China. The APIs are the raw materials for the manufacture of drugs. For example, Paracetamol is the API for Crocin.

We are deeply grateful to our readers & viewers for their time, trust and subscriptions.

Quality journalism is expensive and needs readers to pay for it. Your support will define our work and ThePrint’s future.


In 2018-19, the government had informed the Lok Sabha that the country’s drugmakers imported bulk drugs and intermediates worth $2.4 billion from China.

Infographic by Soham Sen | ThePrint

Also read: India’s production of paracetamol, top antibiotics could be hit by China coronavirus crisis

Government’s assessment

The government committee, chaired by Joint Drug Controller of India Dr. Eswara Reddy, had asked the pharma industry to report the stock in hand of essential medicines and previous consumption trends, said sources.

The other members of the committee include drug associations IDMA, IPA and OPPI, the Directorate General of Foreign Trade (DGFT), the Indian Council of Medical Research (ICMR), the National Pharmaceutical Pricing Authority and the Pharmaceutical Export Promotion Council of India.

“We have been informed by the drugmakers that the top companies have stock for 50-70 days and medium and small enterprises have stocks for 45-50 days,” said a government official who attended the meeting Monday.

Another representative from the lobby of drugmakers said the shortages are likely to occur “if China remained shut even in the later half of this month”.

IDMA, IPA and OPPI represent top domestic and foreign pharma companies operating in India, including Sun Pharma, Lupin, Zydus Cadila, Novartis and Glenmark, among others.

Drug shortage won’t affect patients before next 6 months

Once the product stops at manufacturing sites, it will take at least three months to finish the stock lying at pharmacy stores or with distributors and wholesalers.

According to India’s largest chemist lobby, the All India Organisation of Chemists and Druggists, if companies can continue producing drugs for another three months, patients can easily find the medicines at chemist outlets for the next six months.

“If a factory stops production today, the distributor usually has a stock for one month. (The) Wholesaler, in turn, has a stock for 45 days and retail chemist is also stocked for 15-25 days, which means the supply chain will have drugs for another three months,” said Rajiv Singhal, secretary general, AIOCD. “At the retail level, the shortage won’t come soon.”

Also read: How badly will coronavirus hurt world economy? This is how experts are trying to find out


Subscribe to our channels on YouTube & Telegram

News media is in a crisis & only you can fix it

You are reading this because you value good, intelligent and objective journalism. We thank you for your time and your trust.

You also know that the news media is facing an unprecedented crisis. It is likely that you are also hearing of the brutal layoffs and pay-cuts hitting the industry. There are many reasons why the media’s economics is broken. But a big one is that good people are not yet paying enough for good journalism.

We have a newsroom filled with talented young reporters. We also have the country’s most robust editing and fact-checking team, finest news photographers and video professionals. We are building India’s most ambitious and energetic news platform. And we aren’t even three yet.

At ThePrint, we invest in quality journalists. We pay them fairly and on time even in this difficult period. As you may have noticed, we do not flinch from spending whatever it takes to make sure our reporters reach where the story is. Our stellar coronavirus coverage is a good example. You can check some of it here.

This comes with a sizable cost. For us to continue bringing quality journalism, we need readers like you to pay for it. Because the advertising market is broken too.

If you think we deserve your support, do join us in this endeavour to strengthen fair, free, courageous, and questioning journalism, please click on the link below. Your support will define our journalism, and ThePrint’s future. It will take just a few seconds of your time.

Support Our Journalism

Share Your Views


Please enter your comment!
Please enter your name here